What you can see in the June announcement, OSP has not only surrounded majority of it's future growth around the GE agreement for commercialisation into different countries/regions but also become dependant on GE health in regards to sales of Dyvert and it’s future outlook. The company looks well-funded and has already gone through a term-sheet on the basis of good faith with “anticipation of a definitive agreement to be entered in the near term”. Now we may not know the 100% timing but that latest report definitely provided a direction it wants to head to if you analyse it appropriately.
OSP Price at posting:
4.4¢ Sentiment: Buy Disclosure: Held
